tbuckley/cabot-search huggingface dataset:
Is the Search for Enough Moderate-Severe Ischemia Nearly Over?
Authors: Raymond J. Gibbons
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Shaping of infant B cell receptor repertoires by environmental factors and infectious disease
Authors: Sandra C. A. Nielsen, Krishna M. Roskin, Katherine J. L. Jackson, Shilpa A. Joshi, Parastu Nejad, Ji-Yeun Lee, Lisa E. Wagar, Tho D. Pham, Ramona A. Hoh, Khoa D. Nguyen, Hannah Y. Tsunemoto, Sonal B. Patel, Robert Tibshirani, Catherine Ley, Mark M. Davis, Julie Parsonnet, Scott D. Boyd
Journal: Science Translational Medicine (2019)

Distinct environmental exposures are associated with the maturation of antibody types in early childhood.
Abstract 13276: Triglyceride and Time to ESRD Across CKD Stages With Adjustment for Other Components of Metabolic Syndrome Among 2.1 Million US Veterans
Authors: Melissa Soohoo, Carola-Ellen Kleine, Hamid Moradi, Maria Marroquin, Csaba P Kovesdy, Kamyar Kalantar-Zadeh, Elani Streja
Journal: Circulation (2018)

Introduction: Prior studies evaluating associations between metabolic syndrome and its components (including high triglycerides) with kidney disease incidence have shown conflicting results. Moreov...
Serum cytokeratin 19 fragment 21‐1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease
Authors: Y. Nakamura, K. Tanese, I. Hirai, M. Amagai, Y. Kawakami, T. Funakoshi
Journal: British Journal of Dermatology (2019)

Extramammary Paget disease (EMPD) is a rare intraepithelial adenocarcinoma affecting the genitals and axillary regions. As metastasis of these tumours is itself rare, solid disease management strategies have not been established. Serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment 21‐1 (CYFRA 21‐1) levels have been identified as candidate biomarkers for tumour progression in EMPD. To determine the accuracy of and the correlation between these markers in patients with EMPD. Serum CEA and CYFRA 21‐1 levels were examined in 30 patients with EMPD treated at Keio University Hospital, and compared against clinical information. Both assays were performed at the time of diagnosis, during the postoperative observation period, and following systemic treatment in those with confirmed metastasis. Serum levels were then correlated with tumour progression status and treatment responses. Normal levels for both assays were observed in all 11 patients with primary localized disease (100%). In patients with metastatic disease the CEA positivity rate was 79% (15 of 19 patients), with a rate of 63% (12 of 19 patients) for CYFRA 21‐1. Changes in CEA and CYFRA 21‐1 levels were statistically independent; however, using a combined view, elevated levels of either marker improved the positivity rate to 95% (18 of 19 patients). Use of both markers also correlated well with treatment responses. The combination of CEA and CYFRA 21‐1 is useful for predicting metastasis and treatment response in patients with EMPD, especially in those who only have elevation of a single marker. What's already known about this topic? Serum levels of carcinoembryonic antigen (CEA) and cytokine 19 fragment 21‐1 (CYFRA 21‐1) have been shown to be elevated in patients with extramammary Paget disease (EMPD). Elevation of serum CEA levels is associated with tumour progression of EMPD. A single small study reported that serum CYFRA 21‐1 levels are elevated in patients with EMPD with lymph node metastasis. What does this study add? Serum CEA and CYFRA 21‐1 were present in 79% and 63% of 19 cases of metastatic EMPD, respectively. Elevations of CEA and CYFRA 21‐1 were statistically independent. CEA and CYFRA 21‐1 combination assays were positive in 95% of cases of metastatic EMPD. What is the translational message? Combination assays with CEA and CYFRA 21‐1 are useful for monitoring treatment response in patients with metastatic EMPD, particularly in those with elevation of either marker.
Highlights of the 56th Annual Scientific Session of the American College of Cardiology—March 24–27, 2007
Authors: C. Richard Conti, Anthony N. DeMaria, JoAnne Foody, Robert A. Harrington, Samir R. Kapadia, William D. Knopf, Steven M. Markowitz, John F. Rhodes, Randall C. Starling, James H. Stein, James D. Thomas, E. Murat Tuzcu, Flordeliza Villanueva, Lynne E. Wagoner
Journal: Journal of the American College of Cardiology (2007)
Abbreviated T-Cell Activation on the Automated Clinimacs Prodigy Device Enhances Bispecific CD19/22 Chimeric Antigen Receptor T-Cell Viability and Fold Expansion, Reducing Total Culture Duration
Authors: Sandeep K Srivastava, Sandhya R. Panch, Jianjian Jin, Haneen Shalabi, Nirali N. Shah, Steven L Highfill, David F. Stroncek
Journal: Blood (2018)
US Graduate Medical Education, 2003-2004
Authors: Sarah E Brotherton, Paul H Rockey, Sylvia I Etzel
Journal: JAMA (2004)

Information about recent graduates of medical schools and the characteristics of physicians training in graduate medical education (GME) portends the size and composition of the US physician workforce of the near future.To examine trends in training programs and career choices of graduating male and female residents and to monitor trends in the size of the entire residency population.The American Medical Association and Association of American Medical Colleges jointly surveyed residency programs during the academic year 2003-2004 about active, transferred, and graduated residents, as well as about program characteristics. The 8192 programs confirmed the status of 94.6% of residents. Nearly 86% of program directors (n = 7040) completed the accompanying program survey.Overall trends during the last 6 years in the number and characteristics of residents and programs, as well as the specialty of male and female graduating residents.There were 99,964 active residents during the 2003-2004 academic year, the highest ever recorded by the National GME Census. The number of residents (n = 22,444) entering US graduate medical education programs for the first time is also the highest on record. In 1999, 28,773 physicians completed training, 10,546 (36.7%) of whom were women. In 2003, there were 29,745 graduates, 11,681 (39.3%) of whom were women, representing a 10.8% increase. The number of obstetrics/gynecology male graduates decreased 31.3%, while female graduates increased 18.2%. Other specialties that lost men and gained women were dermatology, family medicine, internal medicine, ophthalmology, pathology, psychiatry, and general surgery. The proportion of graduates who pursued additional training increased; percentages were 27.2% in 1999, 29.6% in 2001, and 32.1% in 2003. In 2000, 35.7% of programs provided opportunities to develop cultural competence; the percentage in 2003 was 50.7%. The percentage of programs with complementary/alternative medicine curriculum has held steady at 24%.The number of physicians in GME is at its highest, and nearly one third of physicians completing training in one program continue on in another. The choices of female residents parallel those of male residents in many respects, but there are important differences.
P019 Is treatment response influenced by body mass index in juvenile idiopathic arthritis?
Authors: T Giani, R Cimaz
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Career situation of first and presenting author</h3> Student for a master or a PhD. <h3>Introduction</h3> There is evidence that obesity could be a risk factor for the severity and response to treatment in patients with RA due both to the mechanical effect of overweight and to the potential pro-inflammatory effects of cytokines produced by adipose tissue. <h3>Objectives</h3> To evaluate the role of overweight and obesity in a cohort of patients with Juvenile Idiopathic Arthritis (JIA), in terms of incidence, disease activity, outcome and response to treatments. <h3>Methods</h3> This single-center retrospective cohort study evaluated 110 children affected by JIA under treatment with anti-rheumatic agents (DMARDs, biologic agents). Changes from baseline in ESR, CRP, number of active joints, and BMI were analyzed under each treatment until last visit. BMI categories of 5–84th (normal weight), 85–94th (overweight), and ≥95th (obese) percentile were used. Patients with systemic JIA, uveitis, chronic comorbidities, or under other potentially confounding systemic treatments were excluded. Uni- and multivariate analyses were performed. <h3>Results</h3> One hundred and ten JIA patients (polyarticular n=50, oligoarticular n=38, psoriatic n=12, enthesitis related arthritis n=8, undifferentiated n=2<i>)</i> were enrolled in the study, 75% girls, 25% boys. The mean age at treatment onset was 6.09 years. Baseline BMI was ≤84 th percentile in 80 patients, 85–94th in 27, and ≥95 th in 3. We did not observe a significant association between BMI and ESR, CRP, or number of active joints at baseline, while involvement of the joints of lower limbs was significantly greater (p=0.025) in overweight/obese patients. We observed a trend toward lower remission rates and higher number of relapses, both after DMARDs and biologics, in patients with higher BMI. <h3>Conclusions</h3> This study focuses on the relationship between overweight/obesity and JIA. A significant correlation between obesity and a greater involvement of the joints of the lower limbs was observed at baseline. Furthermore our data suggest that obesity could negatively influence the course of the disease as well as treatment response. <h3>References</h3> Marques A, Peralta M, Naia A, Loureiro N, de Matos MG. Prevalence of adult overweight and obesity in 20 European countries. <i>Eur J Public Health</i> 2018;28:295–300. Liu Y, Hazlewood GS, Kaplan GG, Eksteen B, Barnabe C. The impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis. <i>Arthritis Care Res (Hoboken)</i> 2017;69:157–65. CF Pelajo, JM Lopez-Benitez, LC Miller. Obesity and disease activity in juvenile idiopathic arthritis. <i>Pediatr Rheumatol</i> 2012;10:3. <h3>Disclosure of Interest</h3> None declared.
P-Gemox Regimen(Pegaspargase, Gemcitabine, oxaliplatin) for Extranodal Natural Killer Cell Lymphoma: 10 Years' Real-World Clinical Experience from China
Authors: Gao Yan, Hui-qiang Huang, Wang Xiaoxiao, Bai Bing, Pengfei Li, Hui Zhou, Zhi-gang Peng, Xiao-yan Ke, Kai-yang Ding, Yu Yang, Sha-dong Min, Yue-rong Shuang, Li Zhiming, Cai Qingqing, Bingzong Li, Wenqi Jiang
Journal: Blood (2018)
Man and the Microbiome: A New Theory of Everything?
Authors: Mary I. Butler, John F. Cryan, Timothy G. Dinan
Journal: Annual Review of Clinical Psychology (2019)

The gut microbiome is implicated in the pathophysiology of a wide range of psychological disorders. Preclinical studies have provided us with key insights into the mechanisms by which the microbiome influences bidirectional gut-brain communication. There are many signaling pathways involved, including the hypothalamic-pituitary-adrenal axis, immune modulation, tryptophan and serotonin metabolism, bile acid transformation, microbial production of neuroactive compounds, and regulation of the endocannabinoid system. The complex and widespread influence of the microbiome on many physiological and psychological processes has generated a keen interest in its therapeutic potential for depression, anxiety, autism, and other psychiatric disorders. It has been shown that the microbiome composition of people suffering with such conditions differs significantly from that of healthy controls, and although the area is in its infancy, interventional studies that alter a person's microbiome through the use of probiotics, prebiotics, or dietary change can alleviate psychopathological symptoms.
Global Routine Vaccination Coverage, 2016
Authors: Leora R. Feldstein, Stephanie Mariat, Marta Gacic-Dobo, Mamadou S. Diallo, Laura M. Conklin, Aaron S. Wallace
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

The Global Vaccine Action Plan 2011-2020 (GVAP) (1), endorsed by the World Health Assembly in 2012, calls on all countries to reach ≥90% national coverage for all vaccines in the country's routine immunization schedule by 2020. CDC and the World Health Organization (WHO) evaluated the WHO and United Nations Children's Fund (UNICEF) global vaccination coverage estimates to describe changes in global and regional coverage as of 2016. Global coverage estimates for the third dose of diphtheria and tetanus toxoids and pertussis-containing vaccine (DTP3), the third dose of polio vaccine, and the first dose of measles-containing vaccine (MCV1) have ranged from 84% to 86% since 2010. The dropout rate (the proportion of children who started but did not complete a vaccination series), an indicator of immunization program performance, was estimated to be 5% in 2016 for the 3-dose DTP series, with dropout highest in the African Region (11%) and lowest in the Western Pacific Region (0.4%). During 2010-2016, estimated global coverage with the second MCV dose (MCV2) increased from 21% to 46% by the end of the second year of life and from 39% to 64% when older age groups (3-14 years) were included (2). Improvements in national immunization program performance are necessary to reach and sustain high vaccination coverage to increase protection from vaccine-preventable diseases for all persons.
Greater Aortic Stiffness and Pulsatile Arterial Load Are Associated With Larger Thoracic Aortic Aneurysm Size in Women
Authors: Jennifer Jue, Munir Boodhwani, Luc Beauchesne, Carole Dennie, Sudhir Nagpal, Kwan-Leung Chan, Thais Coutinho
Journal: Circulation (2019)
TCT-606 BIOTRONIK-Safety and Clinical Performance of the Drug Eluting Orsiro Stent in the Treatment of Subjects With Single De Novo Coronary Artery Lesions-II (BIOFLOW-II) – 2 Year Clinical Results
Authors: Rafael Ruiz-Salmeron, Thierry Lefevre, Michael Haude, Karl Stangl, Ton Slagboom, Franz-Josef Neumann, Manel Sabate, Jean Christophe MACIA, Gert Richardt, Béla Merkely, Goicolea J, Johannes Bilger, Dimitar Divchev, Paul Barragan, Stéphane Cook, Bernhard Witzenbichler, Stephan Windecker
Journal: Journal of the American College of Cardiology (2014)
Update: Influenza Activity — United States, September 29–December 7, 2013
Authors: Lynnette Brammer, Scott Epperson, Lenee Blanton, Krista Kniss, Desiree Mustaquim, Craig Steffens, Rosaline Dhara, Michelle Leon, Alejandro Perez, Sandra Chaves, Jackie Katz, Teresa Wallis, Julie Villanueva, Xiyan Xu, Anwar Isa Abd Elal, Larisa Gubareva, Lyn Finelli, Joseph Bresee, Nancy Cox, Alexander Millman
Journal: MMWR Morbidity and Mortality Weekly Report (2013)
Predicting Drug Response and Novel Therapeutic Candidates Using Signatures of Molecular Alterations in Hematologic Malignancies
Authors: Guillaume Labilloy, Eric O'Brien, Brett VanCauwenbergh, Luke Byerly, Mitali Basu, William Seibel, Erin H. Breese, John Peter Perentesis, Mayur Sarangdhar
Journal: Blood (2018)
The role of translocator protein in prostate cancer
Authors: Arlee Fafalios, Ardavan Akhavan, Anil Parwani, Beth Pflug
Journal: Cancer Research (2007)

311  Translocator protein (TSPO) is an 18kDa cholesterol binding protein involved in various cellular functions. It is primarily localized to the mitochondrial membrane but has also been shown to localize to the nucleus. Although expressed in most tissues, TSPO levels are highest in steroidogenic tissues suggesting a potential hormonal relationship. TSPO has been shown to be upregulated in numerous malignancies, including prostate, breast, ovary, skin, liver, colon, and glial cell. While prostate cancer was one of the first malignancies recognized to have elevated TSPO levels, few studies have examined the role of TSPO in neoplastic transformation of the prostate. In this study, we examined the expression, localization, and function of TSPO in prostate cancer. Prostate tumors and tissues with metastatic prostate lesions were collected from transgenic adenocarcinoma of mouse prostate (TRAMP) mice as well as from nontransgenic littermates and in human prostate tissue samples obtained from the University of Pittsburgh Department of Pathology tissue bank. Both TRAMP and human tissues were analyzed for TSPO expression using immunohistochemistry and scored for tumor grade and intensity of TSPO immmunostaining. Protein and mRNA were harvested from TRAMP tissues and evaluated using immunoblot and RT-PCR analyses, respectively. To investigate TSPO expression and localization in vitro, cellular fractions (nuclear, cytoplasmic, and mitochondrial) were harvested from prostate cancer cell lines differing in their invasive potential and androgen-sensitivity. To identify effects of TSPO antagonism on prostate tumor cell growth and survival, prostate cancer cells were treated with the TSPO antagonists. Results from the immunohistochemical analysis revealed that TSPO expression increased significantly in human prostate adenocarcinoma compared to donor and adjacent benign glands. Immunohistochemical, immunoblot and RT-PCR analyses revealed high levels of TSPO protein and mRNA in TRAMP primary and metastatic prostate lesions. TSPO expression was dramatically increased in highly aggressive cell lines as well as in long-term androgen deprived prostate cancer cell lines, and TSPO was primarily localized to the nuclear and cytoplasmic fractions of these cells. In vitro, the administration of TSPO antagonist, PK11195, significantly increased apoptosis in prostate cancer cells. Together this data demonstrates a correlation between the upregulation of TSPO and prostate cancer cell aggressive phenotype and androgen independency. Additionally, the increase in apoptosis following treatment with a TSPO antagonist suggests that TSPO may play a survival role in prostate cancer.
Comments on “Combined endoscopic submucosal dissection and transanal minimally invasive surgery for resection of large refractory rectal polyp”
Authors: Javier Valdes-Hernandez
Journal: Endoscopy (2019)

See also: Combined endoscopic submucosal dissection and transanal minimally invasive surgery for resection of large refractory rectal polypEndoscopy 2018; 50(05): 548-549DOI: 10.1055/s-0044-101020
PNPLA3, CGI‐58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice
Authors: Yang Wang, Nora Kory, Soumik BasuRay, Jonathan C. Cohen, Helen H. Hobbs
Journal: Hepatology (2019)

A variant (148M) in patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) is a major risk factor for fatty liver disease. Despite its clinical importance, the pathogenic mechanism linking the variant to liver disease remains poorly defined. Previously, we showed that PNPLA3(148M) accumulates to high levels on hepatic lipid droplets (LDs). Here we examined the effect of that accumulation on triglyceride (TG) hydrolysis by adipose triglyceride lipase (ATGL), the major lipase in the liver. As expected, overexpression of ATGL in cultured hepatoma (HuH‐7) cells depleted the cells of LDs, but unexpectedly, co‐expression of PNPLA3(wild type [WT] or 148M) with ATGL inhibited that depletion. The inhibitory effect of PNPLA3 was not caused by the displacement of ATGL from LDs. We tested the hypothesis that PNPLA3 interferes with ATGL activity by interacting with its cofactor, comparative gene identification‐58 (CGI‐58). Evidence supporting such an interaction came from two findings. First, co‐expression of PNPLA3 and CGI‐58 resulted in LD depletion in cultured cells, but expression of PNPLA3 alone did not. Second, PNPLA3 failed to localize to hepatic LDs in liver‐specific Cgi ‐ 58 knockout (KO) mice. Moreover, overexpression of PNPLA3(148M) increased hepatic TG levels in WT, but not in Cgi ‐ 58 KO mice. Thus, the pro‐steatotic effects of PNPLA3 required the presence of CGI‐58. Co‐immunoprecipitation and pulldown experiments in livers of mice and in vitro using purified proteins provided evidence that PNPLA3 and CGI‐58 can interact directly. Conclusion: Taken together, these findings are consistent with a model in which PNPLA3(148M) promotes steatosis by CGI‐58‐dependent inhibition of ATGL on LDs.
SP0156 Theory of poster design and presentation
Authors: M. Boers
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> This lecture introduces basic elements of poster design, and is followed after the session by a special poster tour devoted to design. It strongly links to the concepts discussed in my workshop on data visualisation. To design an effective poster, its message and the intended audience must be clear. Effective posters stand out because they convey their main message almost instantly, and then seduce participants to stay longer and learn more. Much more than oral presentations, posters are about selling your work in competition with all those other people presenting in your session. In a good poster, all elements work together like a symphony orchestra: Title, headings, text, tables, graphs, format, colours, layout, handouts, gimmicks, and … you! For the design process, you need a good plan (including timelines!), good tools (templates, software!) and a ruthless editor. Editing is about throwing out more and more stuff, until finally you reach the point where throwing out more destroys understanding. So the 'orchestra' has single instrumentation, and is wonderfully transparent. Posters are not 'comprehensive'! All the details you love can go into a specially designed handout (NOT an exact replica of your poster). Your role as presenter is special: you must be visible but unobtrusive, and flexible to accommodate different viewer styles, and have different modes of presentation (eg. walkthrough, answer questions, respond to critique). Also make sure your contact details are visible and correct (if no handout, be sure to have business cards). If you are playful you can use gimmicks to increase your visibility: match your clothes to your colour scheme, make something in real 3D on your poster, use sound, etc. But don't overdo it: this is just the icing on the cake: this is a science, not a commercial exhibit. When we go to assess posters in the upcoming poster tour, we will be looking for the following elements: Overall message clear? Text quality: brevity, clarity Table quality: clear vision, clear understanding Graph quality: clear vision, clear understanding Design elements: layout, choice of font, color Handout: not a replica, elements 1–5 repeated Presenter: style, contact details <h3>Disclosure of Interest</h3> None declared
Epigenetic control of early dendritic cell lineage specification by the transcription factor IRF8 in mice
Authors: Daisuke Kurotaki, Wataru Kawase, Haruka Sasaki, Jun Nakabayashi, Akira Nishiyama, Herbert C. Morse, Keiko Ozato, Yutaka Suzuki, Tomohiko Tamura
Journal: Blood (2019)